High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

(2009) Thomas M. Habermann et al.   BRITISH JOURNAL OF HAEMATOLOGY

Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine

(2009) Mar Garcia et al.   CANCER

Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?

(2009) Martin Dreyling et al.   CURRENT OPINION IN ONCOLOGY

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

(2008) C. H. Geisler et al.   BLOOD

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)

(2008) G. M. Mead et al.   BLOOD

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

(2008) Annina Herrmann et al.   JOURNAL OF CLINICAL ONCOLOGY

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

(2007) E. Hoster et al.   BLOOD